SynthesisFrontiers in pharmacology2026
Danshen (
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to systematically assess the effectiveness of Danshen ( Methods: A systematic review and meta-analysis of 35 randomized controlled trials involving animal models of SCI were conducted. Data were extracted regarding the effects of Danshen extract on motor function (measured by the BBB score), inflammation, oxidative stress, apoptosis, and edema. Subgroup analyses based on model type, drug dosage, and compound type were also performed. Results: Danshen extract significantly improved motor function at multiple time points (3, 7, 14, and 21 days post-injury). The BBB scores were higher in the treatment group across all time points (SMD = 4.53 at 3 days, p < 0.001). Additionally, Danshen reduced inflammatory markers (TNF-α, IL-1β), oxidative stress (MDA), and apoptotic markers (Caspase-3), while increasing antioxidant activity (SOD). It also significantly reduced spinal cord edema, as indicated by decreased water content in the injury areas (SMD = -3.88, p < 0.00001). Subgroup analysis showed the most significant improvements in contusion and ischemic models, with higher doses (>20 mg/kg) and water-soluble phenolic acids providing the best outcomes. Conclusion: Danshen extract exhibits significant potential in treating SCI through its diverse mechanisms, such as reducing inflammation, combating oxidative stress, preventing cell death, and alleviating edema. However, further research is needed to refine treatment protocols and establish its clinical relevance. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/recorddashboard.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.